Cell and Gene Regulatory
-
DEA Reveals Hidden Costs Of Analytical Validation Guidelines
10/2/2026
By treating distinct validation guidelines as decision-making units, data envelopment analysis (DEA) allows for the mathematical evaluation of their resource efficiency.
-
Integrated Services That Pass Inspections
10/1/2026
Standardized supply chain workflows reduce risk, protect biological integrity, and enable compliant scaling from clinical trials through commercialization.
-
Align Cryopreservation Services With Regulatory Expectations
10/1/2026
Audit-ready cryopreservation workflows reduce risk, protect biological integrity, and support compliant scaling from research through commercialization.
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
10/1/2026
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
Containment Solutions For API Weighing And Dispensing In Pharmaceutical Manufacturing
9/30/2026
Potency bands and exposure limits are a starting point for containment selection, not the answer. Quantity, dustiness, transfer method and process energy determine whether a control fits weighing and dispensing.
-
What FDA CRLs Reveal About Cell-Based Potency Assays
9/30/2026
Download the white paper to learn what issues are driving these CRLs and how to build a stronger cell-based potency assay strategy.
-
What FDA CRLs Reveal About Stability
9/30/2026
Download our white paper to learn what issues are driving these CRLs and how to build a stronger stability testing program.
-
Advancing The Human Liver-Chip Toward FDA Qualification
9/30/2026
Explore how human-relevant liver models can improve DILI risk assessment and support stronger development decisions while advancing toward regulatory qualification and scaling into automated studies.
-
Bridging Discovery, Developability, And Commercial Reality
9/29/2026
Driven by metabolic and oncology successes, the expanding peptide therapeutics market faces critical challenges requiring early, customized drug product development, stability, and safety strategies.
-
ICH M4Q(R2) And M16 Modernize The CTD For Digital Submissions
9/28/2026
A former FDA assessor explains how recent changes to the common technical document bring long-overdue updates to the submission process, accounting for greater data demands.